NAS:JAZZ (Ireland) Also trade in: Germany

Jazz Pharmaceuticals PLC

$ 136.76 -0.66 (-0.48%)
Volume: 542,867 Avg Vol (1m): 621,098
Market Cap $: 7.80 Bil Enterprise Value $: 8.57 Bil
P/E (TTM): 17.08 P/B: 2.91
Earnings Power Value 81.14
Net Current Asset Value -21.42
Tangible Book -14.96
Projected FCF 151.36
Median P/S Value 189.05
Graham Number 0
Peter Lynch Value 111.72
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.52
Cash-To-Debt ranked lower than
87.38% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
JAZZ: 0.52
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.1, Med: 0.52, Max: 10000
Current: 0.52
0.1
10000
Equity-to-Asset 0.52
Equity-to-Asset ranked lower than
66.97% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
JAZZ: 0.52
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.84, Med: 0.43, Max: 0.87
Current: 0.52
-0.84
0.87
Debt-to-Equity 0.59
Debt-to-Equity ranked lower than
69.60% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
JAZZ: 0.59
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -3.36, Med: 0.58, Max: 9.37
Current: 0.59
-3.36
9.37
Debt-to-EBITDA 1.63
Debt-to-EBITDA ranked lower than
52.04% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
JAZZ: 1.63
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.72, Med: 1.84, Max: 4.97
Current: 1.63
0.72
4.97
Interest Coverage 10.21
Interest Coverage ranked lower than
90.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
JAZZ: 10.21
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 0.7, Med: 9.01, Max: 76.32
Current: 10.21
0.7
76.32
Piotroski F-Score 8
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.07
DISTRESS
GREY
SAFE
Beneish M-Score -2.61
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 17.93%
WACC 6.52%

Profitability & Growth : 9/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 38.87
Operating Margin ranked higher than
92.17% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
JAZZ: 38.87
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 12.4, Med: 37.62, Max: 46.95
Current: 38.87
12.4
46.95
Net Margin % 24.88
Net Margin ranked higher than
91.41% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
JAZZ: 24.88
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -5.32, Med: 24.83, Max: 49.25
Current: 24.88
-5.32
49.25
ROE % 17.16
ROE ranked higher than
91.30% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
JAZZ: 17.16
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 4.38, Med: 21.72, Max: 111.92
Current: 17.16
4.38
111.92
ROA % 9.14
ROA ranked higher than
89.85% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
JAZZ: 9.14
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -6.08, Med: 9.86, Max: 64.21
Current: 9.14
-6.08
64.21
ROC (Joel Greenblatt) % 266.43
ROC (Joel Greenblatt) ranked higher than
95.95% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
JAZZ: 266.43
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 226.17, Med: 630.91, Max: 11377.93
Current: 266.43
226.17
11377.93
3-Year Total Revenue Growth Rate 12.60
3-Year Revenue Growth Rate ranked higher than
68.05% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
JAZZ: 13.7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -2.3, Med: 19.3, Max: 47.7
Current: 13.7
-2.3
47.7
3-Year Total EBITDA Growth Rate 10.50
3-Year EBITDA Growth Rate ranked higher than
76.56% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
JAZZ: 11.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 11.7, Max: 75.7
Current: 11.6
0
75.7
3-Year EPS w/o NRI Growth Rate 11.80
3-Year EPS w/o NRI Growth Rate ranked higher than
99.08% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
JAZZ: 11.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 6.4, Max: 104.6
Current: 11.8
0
104.6

» JAZZ's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:JAZZ

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare SZSE:000661 NAS:TECH NAS:BLUE HKSE:06160 NAS:NBIX SZSE:002252 NAS:MRNA TSE:4587 NAS:SAGE NAS:SRPT NAS:AMRN XAMS:GLPG NAS:EXEL SZSE:002007 NAS:ALNY NAS:NKTR NAS:ASND BOM:532523 NAS:ARRY SZSE:300347
Traded in other countries J7Z.Germany
Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, 4
Jazz Pharmaceuticals is an Ireland-domiciled specialty pharmaceutical firm focused primarily on treatments for orphan drug indications. Jazz's product portfolio includes lead drug Xyrem for narcolepsy, Erwinaze for acute lymphoblastic leukemia, Defitelio for severe veno-occlusive disease, and Vyxeos for acute myeloid leukemia.

Ratios

Current vs industry vs history
PE Ratio (TTM) 17.08
PE Ratio ranked higher than
54.44% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
JAZZ: 17.08
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 10.62, Med: 23.24, Max: 99999999.99
Current: 17.08
10.62
99999999.99
Forward PE Ratio 9.25
Forward P/E ranked higher than
79.22% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
JAZZ: 9.25
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 17.08
PE without NRI ranked higher than
54.32% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
JAZZ: 17.08
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 11.75, Med: 23.09, Max: 99999999.99
Current: 17.08
11.75
99999999.99
Price-to-Owner-Earnings 17.09
Price-to-Owner-Earnings ranked higher than
52.41% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
JAZZ: 17.09
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 8.98, Med: 25.54, Max: 11068.13
Current: 17.09
8.98
11068.13
PB Ratio 2.91
PB Ratio ranked higher than
53.64% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
JAZZ: 2.91
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.54, Med: 4.4, Max: 32
Current: 2.91
2.54
32
PS Ratio 4.20
PS Ratio ranked higher than
66.25% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
JAZZ: 4.2
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.22, Med: 5.84, Max: 12
Current: 4.2
0.22
12
Price-to-Free-Cash-Flow 12.82
Price-to-Free-Cash-Flow ranked higher than
67.76% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
JAZZ: 12.82
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 10.63, Med: 17.18, Max: 91.14
Current: 12.82
10.63
91.14
Price-to-Operating-Cash-Flow 9.90
Price-to-Operating-Cash-Flow ranked higher than
77.62% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
JAZZ: 9.9
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 8.88, Med: 15.06, Max: 55.81
Current: 9.9
8.88
55.81
EV-to-EBIT 11.25
EV-to-EBIT ranked lower than
50.19% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
JAZZ: 11.25
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -22.9, Med: 16.6, Max: 30.9
Current: 11.25
-22.9
30.9
EV-to-EBITDA 8.77
EV-to-EBITDA ranked higher than
58.36% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
JAZZ: 8.77
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -57.8, Med: 13.4, Max: 24.3
Current: 8.77
-57.8
24.3
EV-to-Revenue 4.37
EV-to-Revenue ranked higher than
68.22% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
JAZZ: 4.37
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.5, Med: 6.3, Max: 11.9
Current: 4.37
1.5
11.9
PEG Ratio 1.20
PEG Ratio ranked higher than
61.74% of 115 companies
in the Biotechnology industry.
Industry Max: 99.55, Med: 2.02, Min: 0.06
JAZZ: 1.2
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.49, Med: 0.9, Max: 8.83
Current: 1.2
0.49
8.83
Shiller PE Ratio 31.19
Shiller PE Ratio ranked lower than
65.12% of 86 companies
in the Biotechnology industry.
Industry Max: 11472.38, Med: 42.91, Min: 0.02
JAZZ: 31.19
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 28.28, Med: 58.54, Max: 908.5
Current: 31.19
28.28
908.5
Current Ratio 3.15
Current Ratio ranked lower than
56.98% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
JAZZ: 3.15
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.2, Med: 3, Max: 5.55
Current: 3.15
0.2
5.55
Quick Ratio 3.01
Quick Ratio ranked lower than
54.75% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
JAZZ: 3.01
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.17, Med: 2.89, Max: 5.46
Current: 3.01
0.17
5.46
Days Inventory 150.45
Days Inventory ranked lower than
50.31% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
JAZZ: 150.45
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 70.82, Med: 106.32, Max: 150.45
Current: 150.45
70.82
150.45
Days Sales Outstanding 59.85
Days Sales Outstanding ranked higher than
57.19% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
JAZZ: 59.85
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 34.99, Med: 50.74, Max: 59.85
Current: 59.85
34.99
59.85
Days Payable 128.57
Days Payable ranked higher than
59.89% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
JAZZ: 128.57
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 73.94, Med: 79.42, Max: 134.28
Current: 128.57
73.94
134.28

Dividend & Buy Back

Current vs industry vs history

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.90
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
78.24% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
JAZZ: 0.9
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.87, Med: 2.08, Max: 77.26
Current: 0.9
0.87
77.26
Price-to-Median-PS-Value 0.72
Price-to-Median-PS-Value ranked lower than
57.52% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
JAZZ: 0.72
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.06, Med: 0.95, Max: 1.56
Current: 0.72
0.06
1.56
Price-to-Peter-Lynch-Fair-Value 1.22
Price-to-Peter-Lynch-Fair-Value ranked higher than
60.94% of 64 companies
in the Biotechnology industry.
Industry Max: 13.37, Med: 1.72, Min: 0.02
JAZZ: 1.22
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.68, Med: 1.11, Max: 14.94
Current: 1.22
0.68
14.94
Earnings Yield (Joel Greenblatt) % 8.84
Earnings Yield (Greenblatt) ranked higher than
87.97% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
JAZZ: 8.84
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -175.5, Med: 5.7, Max: 10.9
Current: 8.84
-175.5
10.9
Forward Rate of Return (Yacktman) % 19.35
Forward Rate of Return ranked higher than
90.37% of 135 companies
in the Biotechnology industry.
Industry Max: 107.61, Med: 11.41, Min: -475.79
JAZZ: 19.35
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -43.1, Med: 19.6, Max: 24.8
Current: 19.35
-43.1
24.8

More Statistics

Revenue (TTM) (Mil) $ 1,954.5
EPS (TTM) $ 8.02
Beta 1.01
Volatility % 27.96
52-Week Range $ 113.52 - 184
Shares Outstanding (Mil) 56.66

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 8
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y